ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China · Delayed Price · Currency is CNY 38.30
-0.35 (-0.91%)
At close: Feb 2, 2026
ChengDa Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 372.17 | 330.85 | 413.28 | 411.34 | 415.59 | 372.96 |
Other Revenue | 2.28 | 2.28 | 1.03 | 0.12 | 0.14 | 0.07 |
| 374.46 | 333.13 | 414.3 | 411.46 | 415.73 | 373.04 | |
Revenue Growth (YoY) | -5.87% | -19.59% | 0.69% | -1.03% | 11.44% | 26.90% |
Cost of Revenue | 225.4 | 207.33 | 238.93 | 228.55 | 215.7 | 193.47 |
Gross Profit | 149.06 | 125.8 | 175.37 | 182.92 | 200.02 | 179.57 |
Selling, General & Admin | 119.04 | 99.58 | 85.59 | 88.01 | 66.83 | 56.31 |
Research & Development | 94.21 | 93.71 | 27.46 | 19.44 | 17.22 | 18.98 |
Other Operating Expenses | 6.78 | 4.28 | 3.57 | 4.15 | 2.47 | 3.41 |
Operating Expenses | 224.81 | 195.86 | 117.69 | 112.65 | 87.95 | 77.65 |
Operating Income | -75.75 | -70.06 | 57.68 | 70.27 | 112.08 | 101.92 |
Interest Expense | -0.3 | -0.3 | - | -0.2 | -1.4 | -2.68 |
Interest & Investment Income | 17.36 | 32.81 | 48.19 | 40.25 | 0.26 | 0.47 |
Currency Exchange Gain (Loss) | 2.4 | 2.4 | 1.45 | 4.7 | -1.51 | -3.15 |
Other Non Operating Income (Expenses) | 2.43 | 2.91 | -5.06 | -0.16 | -0.1 | -0.11 |
EBT Excluding Unusual Items | -53.86 | -32.24 | 102.26 | 114.87 | 109.33 | 96.45 |
Gain (Loss) on Sale of Investments | -0.57 | 1.6 | - | 0.39 | - | - |
Gain (Loss) on Sale of Assets | 0.04 | 0.2 | 0 | -0.53 | -0.02 | 41.86 |
Asset Writedown | -3.48 | -2.53 | -3.51 | -3.43 | -2.62 | -1.85 |
Other Unusual Items | 6.23 | 5.78 | 5.5 | 8.81 | 8.6 | 3.06 |
Pretax Income | -51.65 | -27.18 | 104.25 | 120.11 | 115.29 | 139.51 |
Income Tax Expense | -0.26 | 0.46 | 13.15 | 13.63 | 15.01 | 19.91 |
Earnings From Continuing Operations | -51.38 | -27.64 | 91.1 | 106.48 | 100.27 | 119.61 |
Minority Interest in Earnings | -0.34 | -0.46 | -0.12 | 0.01 | 0.16 | 1.57 |
Net Income | -51.72 | -28.1 | 90.98 | 106.48 | 100.44 | 121.17 |
Net Income to Common | -51.72 | -28.1 | 90.98 | 106.48 | 100.44 | 121.17 |
Net Income Growth | - | - | -14.56% | 6.02% | -17.11% | 123.47% |
Shares Outstanding (Basic) | 151 | 152 | 155 | 151 | 116 | 116 |
Shares Outstanding (Diluted) | 151 | 152 | 155 | 151 | 116 | 116 |
Shares Change (YoY) | -0.87% | -1.75% | 2.12% | 30.56% | -0.00% | 9.67% |
EPS (Basic) | -0.34 | -0.18 | 0.59 | 0.70 | 0.87 | 1.04 |
EPS (Diluted) | -0.34 | -0.18 | 0.59 | 0.70 | 0.87 | 1.04 |
EPS Growth | - | - | -16.33% | -18.80% | -17.11% | 103.77% |
Free Cash Flow | -174.51 | -257.72 | -32.6 | -158.03 | -55.56 | 65.16 |
Free Cash Flow Per Share | -1.15 | -1.70 | -0.21 | -1.04 | -0.48 | 0.56 |
Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.188 | 0.281 | - |
Dividend Growth | - | - | 6.67% | -33.34% | - | - |
Gross Margin | 39.81% | 37.76% | 42.33% | 44.45% | 48.11% | 48.14% |
Operating Margin | -20.23% | -21.03% | 13.92% | 17.08% | 26.96% | 27.32% |
Profit Margin | -13.81% | -8.44% | 21.96% | 25.88% | 24.16% | 32.48% |
Free Cash Flow Margin | -46.60% | -77.36% | -7.87% | -38.41% | -13.36% | 17.47% |
EBITDA | -24.22 | -23.22 | 98.28 | 105.58 | 142.56 | 128.26 |
EBITDA Margin | -6.47% | -6.97% | 23.72% | 25.66% | 34.29% | 34.38% |
D&A For EBITDA | 51.53 | 46.85 | 40.6 | 35.32 | 30.49 | 26.34 |
EBIT | -75.75 | -70.06 | 57.68 | 70.27 | 112.08 | 101.92 |
EBIT Margin | -20.23% | -21.03% | 13.92% | 17.08% | 26.96% | 27.32% |
Effective Tax Rate | - | - | 12.61% | 11.35% | 13.02% | 14.27% |
Revenue as Reported | 374.46 | 333.13 | 414.3 | 411.46 | 415.73 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.